Lonza Pharma Biotech & Nutrition (LBPN)

Our Offerings

As a leading company for contract development and manufacturing, our LPBN segment is recognized for its reliable, high-quality services, regulatory track record, global footprint, innovative technology platforms and extensive experience.

Our vision is to enable our customers to meet some of the greatest challenges in patient treatment. We cover a wide range of services within the biopharma industry. Our broad capabilities span biologics, small molecules (including highly potent active pharmaceutical ingredients such as cytotoxins), bioconjugates and cell and gene technologies. We support projects from research, discovery and pre-clinical stages, through clinical trials to commercialization and our expertise extends across both drug substance and drug product.

Pharma & Biotech Contribution to the Value Chain

This has images

The LPBN segment includes the following offerings:

  • Capsules & Health Ingredients
  • Small Molecules
  • Biologics
  • Cell & Gene Technologies
  • Bioscience
 

Development and Manufacturing Sites

 

R&D Sites

 

Employees (Full-Time Equivalent)

> 

Pre-clinical and Clinical Small 1 and Large 2 Molecules

> 

Commercial Small 1 and Large 2 Molecules

  1. Including active pharmaceutical ingredients (API), highly potent API (HPAPI), dosage form and delivery systems and particle engineering

  2. Including mammalian, microbial, cell & gene therapy products and bioconjugates (applied protein services and drug product services are included for pre-clinical and clinical molecules only)

Personal Perspectives

Stefan Stoffel

Chief Operating Officer (COO) Pharma & Biotech

In 2020, our Technical Operations community has shown strong progress on execution performance, which has enabled us to successfully deliver more than 1,000 customer projects across 37 sites worldwide. Moreover, we have commenced operations on a significant number of organic growth projects, supported by a steep hiring increase. Throughout the year, we have onboarded around 2,000 new operations employees in both our base business and strategic growth investments.

Discover More

Financial Highlights

In 2020, the Lonza Pharma Biotech & Nutrition (LPBN) segment achieved 12.2%1  sales growth and a 32.1% CORE EBITDA margin. We saw a strong performance across our businesses, with Biologics remaining a primary driver of growth. The LPBN segment demonstrated resilience to the impacts of COVID-19. Facilities remained open and supply chains were managed to ensure business continuity. The business worked diligently to expand service offerings to customers while investing in production capacity in response to continued demand.

  1. Sales growth at constant exchange rate (CER)

Pharma Biotech & Nutrition

Million CHF20202019Change in %
Sales4,4724,1677.3
CORE EBITDA1,4361,3714.7
Margin in %32.1 32.9 
CORE result from operating activities (EBIT)1,1721,1254.2
Margin in %26.2 27.0 

Sales

Million CHF

This has images
  1. Reported pro-forma full-year 2017 financial results include Capsugel full-year 2017 financial results
  2. Restated to reflect the 2019 realignment of Lonza’s segments into Pharma Biotech & Nutrition and Specialty Ingredients

CORE EBITDA

Million CHF

CORE EBITDA Margin

In %

This has images
  1. Reported pro-forma full-year 2017 financial results include Capsugel full-year 2017 financial results
  2. Restated to reflect the 2019 realignment of Lonza’s segments into Pharma Biotech & Nutrition and Specialty Ingredients